Order Article Reprints

Houvenaeghel G, Classe J-M, Chauvet M-P, Colombo P-E, Jouve E, Reyal F, Daraï E, Rouzier R, Faure-Virelizier C, Gimbergues P, et al. Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. Cancers. 2024; 16(19):3317. https://doi.org/10.3390/cancers16193317

Houvenaeghel, Gilles, Jean-Marc Classe, Marie-Pierre Chauvet, Pierre-Emmanuel Colombo, Eva Jouve, Fabien Reyal, Emile Daraï, Roman Rouzier, Christelle Faure-Virelizier, Pierre Gimbergues, and et al. 2024. "Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery" Cancers 16, no. 19: 3317. https://doi.org/10.3390/cancers16193317

Houvenaeghel, G., Classe, J.-M., Chauvet, M.-P., Colombo, P.-E., Jouve, E., Reyal, F., Daraï, E., Rouzier, R., Faure-Virelizier, C., Gimbergues, P., Coutant, C., Mazouni, C., Azuar, A.-S., Martino, M., Bouteille, C., Cohen, M., & de Nonneville, A. (2024). Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. Cancers, 16(19), 3317. https://doi.org/10.3390/cancers16193317